Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01420926 · ClinicalTrials.gov registry record · Phase 2
Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia
A Phase 2 study of Acute Myeloid Leukemia and Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
- 20
- Study locations
NCT01420926 is a Phase 2 study of Acute Myeloid Leukemia and Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 165 participants, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (43% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT01420926, a Phase 2 study of Acute Myeloid Leukemia and Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase II trial studies how well giving decitabine with or without bortezomib works in treating older patients with acute myeloid leukemia. Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells,by stopping them from dividing, or by stopping them from spreading. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether decitabine works better when given with or without bortezomib in treating acute myeloid leukemia.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Decitabine
- OTHER Laboratory Biomarker Analysis
- DRUG Bortezomib
- OTHER Pharmacological Study
Study Locations (20)
Michigan
- Bronson Battle Creek - Battle Creek
- Spectrum Health Big Rapids Hospital - Big Rapids
- Cancer Research Consortium of West Michigan NCORP - Grand Rapids
- Mercy Health Saint Mary's - Grand Rapids
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Delaware
- Beebe Medical Center - Lewes
- Christiana Care Health System-Christiana Hospital - Newark
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
- NorthShore University HealthSystem-Evanston Hospital - Evanston
Maine
- Harold Alfond Center for Cancer Care - Augusta
- Eastern Maine Medical Center - Bangor
California
- Palo Alto Medical Foundation-Camino Division - Mountain View
Connecticut
- Hartford Hospital - Hartford
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2011-11-16 |
| Est. Completion | 2021-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01420926
The ClinicalTrials.gov registry entry for NCT01420926 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (43% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.
NCT01420926 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Michigan, Massachusetts, Delaware.
Frequently Asked Questions
What is clinical trial NCT01420926 about?
NCT01420926 is a clinical study titled "Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia". This randomized phase II trial studies how well giving decitabine with or without bortezomib works in treating older patients with acute myeloid leukemia. Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells,by stoppin...
What is the current status of trial NCT01420926?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2011-11-16. Estimated completion is 2021-04-01.
What conditions does trial NCT01420926 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Therapy-Related Acute Myeloid Leukemia.
What interventions are being tested in trial NCT01420926?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Decitabine (DRUG), Laboratory Biomarker Analysis (OTHER), Bortezomib (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT01420926?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01420926 being conducted?
This trial has 20 study locations across California, Connecticut, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
RECRUITING · Phase 2
-
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
RECRUITING · Phase 2
Explore more on PlainTrial
Acute Myeloid Leukemia
All registered trials for this condition
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.